Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Gross Margin (2017 - 2020)

Ironwood Pharmaceuticals' Gross Margin history spans 7 years, with the latest figure at 99.23% for Q4 2020.

  • For Q4 2020, Gross Margin rose 795.0% year-over-year to 99.23%; the TTM value through Dec 2020 reached 99.19%, up 644.0%, while the annual FY2020 figure was 99.19%, 477.0% up from the prior year.
  • Gross Margin for Q4 2020 was 99.23% at Ironwood Pharmaceuticals, down from 100.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 100.0% in Q2 2020 and bottomed at 83.58% in Q4 2018.
  • The 4-year median for Gross Margin is 95.61% (2018), against an average of 94.85%.
  • The largest annual shift saw Gross Margin crashed -689bps in 2018 before it skyrocketed 1107bps in 2020.
  • A 4-year view of Gross Margin shows it stood at 90.46% in 2017, then decreased by -8bps to 83.58% in 2018, then rose by 9bps to 91.28% in 2019, then grew by 9bps to 99.23% in 2020.
  • Per Business Quant, the three most recent readings for IRWD's Gross Margin are 99.23% (Q4 2020), 100.0% (Q3 2020), and 100.0% (Q2 2020).